Avoro Capital Advisors
Crossover fundNew York · Seed–Series A · 22 people tracked
Investment thesis
Avoro Capital Advisors seeks scientific breakthroughs with the potential to address unmet medical needs, driven by intellectual curiosity. The firm aims to identify unique or mispriced investment opportunities, analyzing complex situations and supporting companies with both financial and intellectual resources across the lifecycle of an investment. It emphasizes disciplined risk management, evaluating macro and company-specific risks, and may employ tactical and fundamental hedges within its portfolio construction while carefully weighing position sizing and liquidity considerations.
Source: firm website, verified Aug 25, 2026.
Team · 22 people
from the firm's website & public directories
What they invest in
from 55 of 69 portfolio companiesBiotech ×52Healthtech ×40Medical Devices ×21Deep Tech ×10Digital Health ×4AI & Machine Learning ×3Longevity ×2Cloud Computing ×1
HQs:United States×32Switzerland×1Denmark×1Netherlands×1
Who they back
founder profiles across 21 portfolio companiesFounding team size:solo founder×142 founders×33 founders×14+ founders×3
Investments · 69 tracked
founders shown can be your intro pathBy year:2022 · 12021 · 22020 · 12018 · 12017 · 42015 · 32014 · 113 dated
Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.
BiotechHealthtechMedical DevicesSouth San Francisco, US
ROBERT ABRAHAM(Director)JOSHUA A. KAZAM(Executive Officer, Director)DAVID M. TANEN(Executive Officer)FRANZ HUMER(Director)JOHN DEYOUNG(Director)
BoardOWEN WITTE(Director)
Co-investorsForesite CapitalTPGVida Ventures
Hemab develops targeted therapies for bleeding and clotting disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAccess BiotechnologyHealthCapNovo HoldingsSofinnova Partners
Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.
BiotechDeep TechHealthtechCambridge, US
Nessan Bermingham(Executive Officer, Director)Jennifer Doudna(Co-founder)Jose Rivera(Executive Officer)John Leonard(President and Chief Executive Officer)James Basta(Executive Vice President, General Counsel and Corporate Secretary)Edward Dulac(Executive Vice President, Chief Financial Officer)
Co-investorsage1Atlas VentureEcoR1 CapitalForesite Capital
Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
BiotechDigital HealthMedical DevicesLa Jolla, US
TROY WILSON(Executive Officer, Director)inPINGDA REN(Executive Officer)inYI LIU(Executive Officer)inTroy Wilson(Founder)inHEIDI HENSON(Executive Officer)inANNETTE NORTH(Executive Officer)
Co-investorsARCH Venture PartnersEcoR1 CapitalForesite CapitalNextech InvestOUP (Osage University Partners)
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Nello Mainolfi(Founder)in
Co-investorsAtlas VentureBain Capital Life SciencesBessemer Venture PartnersHatteras Venture PartnersMRL Ventures FundNextech Invest+3 more
Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets.
AI & Machine LearningBiotechDeep TechHealthtechBoston, US
Markus Warmuth(M.D., Chief Executive Officer)inSharon Townson(Ph.D., Chief Scientific Officer)inJohn Castle(Ph.D., Chief Data and Information Officer)inFilip Janku(M.D., Ph.D., Chief Medical Officer)inPhil Nickson(Ph.D., J.D., Chief Business and Legal Officer)inMagnus Walter(DPhil, Chief Technology Officer)in
Co-investorsAisling CapitalNew Enterprise Associates (NEA)Versant VenturesHBM PartnersAmzak HealthGV (Google Ventures)+1 more
BiotechIselin, US
Pankaj Mohan(Executive Officer, Director)Lawrence A. Kenyon(Executive Officer, Director)inJeff Evanson(Executive Officer)in
BoardFaisal G. Sukhtian(Director)Yezan Haddadin(Director)Andong Huang(Director)
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Benjamin Oakes(Founder & CEO)Jennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)
BoardVijay Pande(Director)in
Co-investorsAndreessen HorowitzOrbiMedMenlo VenturesRA CapitalAvoro Ventures
Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies in areas such as metabolic and endocrine disorders.
BiotechHealthtechLongevitySan Diego, US
Brian Lian(President, CEO & Director (Founder))Michael Morneau(Chief Financial Officer)Dr. Lian(President & Chief Executive Officer, Director)Stephen W. Webster(Director)Matthew W. Foehr(Director)
BoardJ. Matthew Singleton(Director)
Ethyreal Bio is a biopharmaceutical company developing medicines for people with Thyroid Eye Disease and Graves' Disease.
BiotechHealthtechCambridge, US
Niranjan Kameswaran(Chief Executive Officer)inJessica Stromme(Chief Development Officer)Kelly Foster(Chief Scientific Officer)Stephen Huang(Senior Vice President, Head of Clinical Development)
BoardSimon Read(Chairman of the Board and Independent Board Member)
Co-investorsAtlas VentureMedicxi
Co-investorsFrazier Life Sciences
Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.
BiotechHealthtechMedical Devices
Co-investorsEight Roads VenturesF-Prime CapitalNew Enterprise Associates (NEA)Ridgeback Capital
Adverum is a clinical-stage gene therapy company developing Ixo-vec, an investigational single-administration intravitreal treatment for wet age-related macular degeneration and other ocular diseases, based on a proprietary adeno-associated virus (AAV) vector platform.
BiotechDeep TechHealthtech
Co-investorsFrazier Life Sciences
Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.
BiotechHealthtechMedical DevicesBedminster, US
CASEY KOPCZYNSKI(Executive Officer)inVICENTE ANIDO(Executive Officer, Director)BRIAN LEVY(Executive Officer)RICHARD RUBINO(Executive Officer)THOMAS MITRO(Executive Officer)
BoardANAND MEHRA(Director)
Co-investorsAlta PartnersForesite CapitalOUP (Osage University Partners)Sofinnova Ventures
Amarin Corporation is a cardiovascular health pharmaceutical company developing treatments to prevent cardiovascular disease.
BiotechHealthtechMedical Devices
Co-investorsFountain Healthcare PartnersLongitude CapitalSignet Healthcare PartnersSofinnova Ventures
Amicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions.
BiotechHealthtechCranbury, US
Daphne Quimi(Executive Officer)John Crowley(Executive Officer, Director)William D. Baird, III(Executive Officer)
BoardCraig A. Wheeler(Director)Ted W. Love(Director)Margaret G. McGlynn(Director)
Co-investorsCanaan PartnersFrazier Life SciencesNew Enterprise Associates (NEA)Prospect Venture Partners
Amylyx is a biopharmaceutical company developing novel therapies for diseases with high unmet medical needs.
BiotechHealthtech
Joshua Cohen(Founder)in
Co-investorsAlpha Wave Global
Co-investorsEpidarex CapitalF-Prime CapitalKeyhorse CapitalSofinnova VenturesSolasta VenturesvenBio Partners
The company develops therapies for people with severe autoimmune diseases.
BiotechHealthtechMedical Devices
Co-investorsMPM BioImpactPMV
Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.
BiotechHealthtechMedical DevicesDenmark, DK
Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)inJan M?ller Mikkelsen(Executive Officer, Director)Grethe Rasmussen(Executive Officer)Harald Rau(Executive Officer)Martin Olin(Director)Lotte S?nderbjerg(Executive Officer)
Co-investorsVivo CapitalAisling CapitalForesite CapitalRA CapitalSofinnova Ventures
Assembly Bio is a biopharmaceutical company developing novel therapeutic candidates for viral and liver diseases, including programs targeting herpesviruses, hepatitis delta virus, hepatitis B virus, and cholestatic liver diseases.
BiotechHealthtechMedical Devices
Jason Okazaki(Chief Executive Officer & President)William Delaney, PhD(Chief Scientific Officer)Anuj Gaggar, MD, PhD(Chief Medical Officer)
Co-investorsLongitude Capital
BiotechBuffalo, US
Flint Besecker(Executive Officer, Director)Li Shen(Executive Officer)Simon Pedder(Executive Officer)Johnson Lau(Executive Officer, Director)William Zuo(Executive Officer)Rudolf Kwan(Executive Officer)
Co-investorsSalica Investments
Co-investorsTrinity Innovation Bioventure SingaporeVivo Capital
Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases.
BiotechDeep TechHealthtechMedical Devices
Co-investorsBrace PharmaF-Prime CapitalFrazier Life SciencesMoore Venture Partners
Co-investorsRapha Capital Management, LLCSolasta Ventures
Co-investorsNew Enterprise Associates (NEA)Sofinnova Ventures
BiotechHealthtechCambridge, US
Michael R. Cooper(Executive Officer)inJames E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)Tom Maniatis(Director)
Co-investorsBain Capital Life SciencesVenrockThe Column GroupThird Rock Ventures
Corvus Pharmaceuticals is a biopharmaceutical company developing immunology-focused medicines that target cellular components of the immune system, with therapeutic focus on immune diseases and cancer.
BiotechHealthtechBurlingame, US
Richard A. Miller(President & CEO, Co-Founder)Leiv Lea(Executive Officer)
BoardElisha (Terry) P. Gould(Director)Peter Moldt(Director)Peter Thompson(Co-Founder)Terry G. Gould(Director)
Co-investorsForesite CapitalOrbiMed
CRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology.
BiotechDeep TechHealthtechZug, CH
Emmanuelle Charpentier(Co-founder)Samarth Kulkarni(Chief Executive Officer and Chairman of the Board)inJames R. Kasinger(General Counsel and Secretary)Stephen Kennedy(Head of Technical Operations)Megan Wherry Menner(Head of Human Resources)Naimish Patel(Chief Medical Officer)
Co-investorsNew Enterprise Associates (NEA)
Gilead Sciences is a biopharmaceutical company headquartered in Foster City, California that discovers, develops, and delivers medicines across virology, oncology, and inflammation.
BiotechHealthtechMedical DevicesNewark, US
Harold Van Wart, Ph. D.(Executive Officer, Director)Pol Boudes(Executive Officer)Charles A. McWherter, Ph. D.(Executive Officer)Sujal Shah(Executive Officer)
BoardCarl Goldfischer, M.D.(Director)Kurt von Emster(Director)
Co-investorsBay City CapitalForesite CapitalVantagePoint Capital Partners
Design Therapeutics is a biopharmaceutical company developing small molecule therapeutic candidates for serious genetic diseases through its GeneTAC (Gene Targeted Chimera) platform.
BiotechMedical Devices
Co-investorsQuan CapitalWestRiver Group
Co-investorsAccess Biotechnology
Fennec Pharmaceuticals develops treatments for cisplatin-induced hearing loss, a side effect of cancer chemotherapy.
BiotechHealthtechMedical DevicesResearch Triangle Park, US
Krysia Lynes(Executive Officer)Rostislav Raykov(Executive Officer, Director)
BoardAdrian Haigh(Director)Steven Skolsky(Director)Chris Rallis(Director)Khalid Islam(Director)
Co-investorsAisling Capital
HedgeServ provides a cloud-based investor services platform for investment managers that automates fund administration tasks including investor onboarding, capital calls, distributions, and reporting.
Cloud ComputingFintechSaaS
Co-investorsGolub Growth
BiotechHealthtech
Co-investorsAtlas VentureNew Enterprise Associates (NEA)
IOBiotech appears to be a biotech company focused on oncology, with a founder who has extensive experience in cancer drug development and clinical advancement from roles at Roche, Eli Lilly, and leading academic cancer centers.
BiotechMedical Devices
Dr. Dhingra
Co-investorsEIR VenturesKurma PartnersRA CapitalSamsara BioCapitalSunstone CapitalVivo Capital+2 more
Iovance develops TIL (tumor-infiltrating lymphocyte) therapy, a personalized cancer treatment that isolates immune cells from a patient's tumor, expands them in a centralized facility using proprietary manufacturing processes, and returns them for infusion back into the patient.
BiotechHealthtechMedical DevicesPhiladelphia, US
Co-investorsSamsara BioCapitalVivo Capital
Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma.
BiotechHealthtechNewton, US
Stuart Poulton(Executive Officer)inMichael Mano(Executive Officer)inReshma Rangwala(Executive Officer)inRichard Paulson(Executive Officer, Director)inStephen Mitchener(Executive Officer)inMichael Mason(Executive Officer)in
Co-investorsForesite CapitalHEALTHCARE ROYALTY PARTNERS
Krystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions.
BiotechHealthtechMedical DevicesPittsburgh, US
Suma M. Krishnan(Director)Krish S. Krishnan(Chairman & CEO)Suma Krishnan(President, Research & Development)inKrish Krishnan(Chairman & CEO)inDoug Norby(Director)Dino Rossi(Director)
Co-investorsFrazier Life SciencesAlta Partners
Madrigal Pharmaceuticals is a biopharmaceutical company developing treatments for metabolic-associated steatohepatitis (MASH).
BiotechHealthtechMedical DevicesConshohocken, US
Rebecca Taub(Founder and Director)
Co-investorsBay City Capital
BiotechRadnor, US
Scott Braunstein, MD(Executive Officer, Director)Edward F. Smith(Executive Officer)Joe Hulihan, MD(Executive Officer)
BoardNicole Vitullo(Director)Enrique J. Carrazana, MD(Director)Michael R. Dougherty(Director)
Co-investorsBain Capital Life SciencesCanaan PartnersConnecticut InnovationsSofinnova VenturesDomain AssociatesFlare Capital Partners+1 more
Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications.
BiotechMedical DevicesUtrecht, NL
Ton Logtenberg(Executive Officer, Director)inMark Throsby(Executive Officer)inHui Liu(Executive Officer)inJohn Crowley(Executive Officer)inL. Andres Sirulnik(Executive Officer)inLex Bakker(Executive Officer)in
Co-investorsPfizer Venture InvestmentsRA CapitalSofinnova Ventures
HealthtechCambridge, US
Matthew Shair(Director)inR. Porter James(Executive Officer, Director)Alex Balcom(Executive Officer)in
BoardAndrew Hack(Director)inCameron Wheeler(Director)Joseph Pearlberg(Director)
Co-investorsBain Capital Life Sciences
Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance.
BiotechHealthtechSan Francisco, US
Co-investorsBain Capital Life SciencesLightspeed Venture PartnersRA Capital
Ottimo Pharma is a clinical-stage biotech company developing PD-1/VEGFR2 dual-paratopic antibodies for cancer treatment.
Biotech
Co-investorsOrbiMed
PMV Pharma develops precision oncology therapies that target and structurally correct mutated p53 proteins to restore their tumor-suppressing function.
BiotechHealthtechCranbury, US
David H. Mack, Ph.D.(Founder)inDavid Mack(Executive Officer, Director)Arnold Levine(Director)
BoardPeter Thompson(Director)Steve Winick(Director)Arnold Oronsky(Director)
Co-investorsNextech InvestOUP (Osage University Partners)RA CapitalOrbiMedOsage University Partners
Praxis Precision Medicines is a central nervous system precision neuroscience biopharmaceutical company developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, with a pipeline spanning movement disorders and epilepsy.
BiotechDeep TechHealthtech
Co-investorsCapria VenturesOCV PartnersAlameda ResearchNorwest Venture Partners
Co-investorsSanofi Ventures
Rocket Pharmaceuticals develops gene therapies to treat patients with rare genetic diseases, focusing on cardiovascular and hematologic disorders.
BiotechDigital HealthMedical Devices
Gaurav Shah(Co-founder & Chief Executive Officer)
BoardRoderick Wong(Director)inNaveen Yalamanchi(Director)in
Co-investorsBroadview VenturesCivilization Ventures Management, LlcRTW Investments L.P.
Sarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions.
BiotechHealthtechCambridge, US
WILLIAM CIAMBRONE(Executive Officer)DOUGLAS S. INGRAM(Executive Officer, Director)inDAVID TYRONNE HOWTON(Executive Officer)SANDESH MAHATME(Executive Officer)GILMORE O'NEILL(Executive Officer)ALEXANDER CUMBO(Executive Officer)
Co-investorsRoche Venture Fund
BiotechBoston, US
Adam Friedman(Executive Officer, Director)inGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)Darrin Stuart(Executive Officer)Erica Jackson(Executive Officer)Amanda Valentino(Executive Officer)
Co-investorsAtlas VentureEcoR1 CapitalFrazier Life SciencesNextech InvestVida VenturesLightspeed Venture Partners+2 more
Stemline is an oncology-focused pharmaceutical company developing and commercializing cancer therapies, including ELZONRIS (tagraxofusp-erzs) for blastic plasmacytoid dendritic cell neoplasm and ORSERDU (elacestrant) for ER-positive, HER2-negative, ESR-1 mutated advanced or metastatic breast cancer.
BiotechHealthtechNew York, US
Ivan Bergstein, M.D.(Executive Officer, Director)
BoardRonald Bentsur(Director)
Co-investorsAisling CapitalBioBritDelos CapitalEcoR1 Capital
Co-investorsLongitude CapitalScion Life SciencesTCG CrossoverVivo Capital
BiotechSouth San Francisco, US
Gerrit Klaerner(Executive Officer, Director)Melissa Miksch(Executive Officer)
BoardSandra Coufal(Director)David Bonita(Director)inKlaus Veitinger(Director)inRobert Alpern(Director)
Co-investorsLongitude CapitalOrbiMed
Vanqua Bio is a biotechnology company developing molecules intended to become medicines for neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and related neurological conditions.
BiotechDeep TechHealthtechLongevityChicago, US
Jim Sullivan(CEO)Kevin Hunt(CSO)
Co-investorsOrbiMedPontifax Venture Capital
AI & Machine LearningBiotechHealthtech
Co-investorsMedicxiTCG CrossoverUniQuest Extension Fund (UEF)venBio Partners
Viveve publishes evidence-based health guides covering six core topics—heart health, women's health, nutrition, hormones, sexual health, and aging—written without pseudoscience or supplement marketing.
Digital HealthHealthtechMedia & EntertainmentWellness & Fitness
Co-investors5AM Ventures
Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.
AI & Machine LearningBiotechDeep TechPrinceton, US
Ben Cravatt(Scientific Founder)Phil Baran(Scientific Founder)Jin-Quan Yu(Scientific Founder)
BoardJohn Park(Executive Officer)John Clarke(Executive Officer, Director)in
Co-investorsARCH Venture PartnersCardinal PartnersNextech InvestSoftBank Vision FundVersant Ventures
Xenon is a neuroscience-focused biopharmaceutical company that discovers and develops ion channel modulators as therapeutics for neurological and psychiatric disorders.
BiotechHealthtech
Ian Mortimer(President and Chief Executive Officer)inDarren Cline(Chief Commercial Officer)Andrea DiFabio(Chief Legal Officer and Corporate Secretary)James Empfield(Executive Vice President, Drug Discovery)Tucker Kelly(Chief Financial Officer)inChris Kenney(Chief Medical Officer)
Co-investorsNew Enterprise Associates (NEA)
Co-investorsKurma PartnersOberland CapitalSunstone Capital
Co-investorsDecheng Capital
Exits · 13
IPOs and acquisitions across the tracked portfolioAllogene TherapeuticsNASDAQ: ALLOHemab TherapeuticsNASDAQ: COAGIntellia TherapeuticsNASDAQ: NTLAKura OncologyNASDAQ: KURAKymera TherapeuticsNASDAQ: KYMRMonte Rosa TherapeuticsNASDAQ: GLUEOutlook TherapeuticsNASDAQ: OTLKScribe TherapeuticsNASDAQ: SCTXViking TherapeuticsNASDAQ: VKTXConstellation Pharmaacq. by NovartisHorizon Therapeuticsacq. by AmgenVicebioacq. by SanofiVividion Therapeuticsacq. by Bayer
Portfolio news
latest coverage across their companiesOutlook Therapeutics · boerse-express.com · Aug 24, 2026
Amylyx · fool.com · Aug 21, 2026
Corvuspharma · insidermonkey.com · Aug 17, 2026
Amicus Therapeutics · dailypolitical.com · Aug 15, 2026
Sarepta Therapeutics · finance.yahoo.com · Aug 1, 2026
Ascendis Pharma · dailypolitical.com · Jul 18, 2026
Frequently asked questions
- How many investments has Avoro Capital Advisors made?
- Avoro Capital Advisors has 69 tracked investments, 5 of which have exited via acquisition or IPO.
- What stage does Avoro Capital Advisors invest at?
- Avoro Capital Advisors invests at the Seed, Series A stages.
- What sectors does Avoro Capital Advisors focus on?
- Avoro Capital Advisors focuses on Biotech, Healthtech.
- Where is Avoro Capital Advisors located?
- Avoro Capital Advisors is headquartered in New York, US.
- Who does Avoro Capital Advisors co-invest with?
- Avoro Capital Advisors most often shares deals with Foresite Capital, New Enterprise Associates (NEA), Sofinnova Ventures, among 82 tracked co-investors.
Co-investors · 10
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.
Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.
Omega Funds invests in venture capital and growth equity opportunities across the life sciences sector.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
Innovation Works is a nonprofit early-stage investor supporting the growth of Southwestern Pennsylvania's tech economy through venture funding, accelerator programs, and ecosystem support.
Riverfront Ventures is an early-stage venture capital fund based in Pittsburgh that invests in early-growth stage technology companies, serving as the venture capital arm of Innovation Works.
Pappas Capital is a life sciences venture capital firm that invests in and helps build companies developing next-generation life science products and technologies.
Firms observed investing alongside Avoro Capital Advisors, from public investor directories. Shared companies are the overlap with Avoro Capital Advisors's recorded portfolio.
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.